Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
Fig 2
The raltegravir-raltegravir glucuronide (parent-metabolite) compartment model.
N1 denotes the first hypothetical transit compartment up to Nn compartment. ktr is the transit rate constant. ka is the absorption rate constant from the hypothetical drug depot compartment to plasma. CL/V (or k) is the elimination rate constant of raltegravir. FMET is the fraction of raltegravir clearance for the formation of raltegravir glucuronide. VM, the distribution volume of the metabolite, was fixed to 1. As such, FMET is estimated as the ratio of the formation rate of glucuronide to VM. CLM is the glucuronide clearance.